Rockville, MD — April 14, 2026

Xcellon Biologics highlights recent industry momentum following the announcement that CrossBridge Bio will be acquired by Eli Lilly and Company for up to $300 million.

CrossBridge Bio is a portfolio company of Linden Lake Labs, the parent platform of Xcellon Biologics. The transaction represents a rapid seed-to-acquisition outcome. It also reflects continued investment in next-generation antibody drug conjugate platforms, including dual payload systems.

As part of the Linden Lake Labs platform, Xcellon Biologics is building development and manufacturing capabilities in Rockville, Maryland. The focus is on antibody drug conjugates, bispecific antibodies, and T cell engagers.

The company supports ADC programs from early design through process development. In addition, it is advancing toward GMP manufacturing to enable clinical and commercial supply.

“The CrossBridge transaction reflects continued focus on complex biologics and next-generation ADC design,” said Yuk Chun Chiu, Co-Founder and COO of Xcellon Biologics. “As these programs evolve, the ability to translate design into controlled and scalable processes becomes critical.”

As complexity increases in ADC design, early integration of chemistry, analytics, and manufacturability becomes more important. Therefore, development strategies are shifting earlier. Xcellon Biologics continues to expand capabilities in bioconjugation, analytical development, and scalable manufacturing to support these programs.

The CrossBridge Bio acquisition reflects continued activity in the ADC space. More importantly, it highlights the need for alignment between discovery, development, and manufacturing as programs advance.

Learn more about Xcellon Biologics’ ADC development and manufacturing capabilities.

Read the full coverage on BioBuzz.